Biologics Manufacturing Market To Reach $140.62 Billion By 2033

Biologics Manufacturing Market Growth & Trends

The global biologics manufacturing market size is projected to reach USD 140.62 billion by 2033, growing at a CAGR of 17.0% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market for biologics manufacturing is expanding significantly due to the increased demand for recombinant proteins, vaccines, cell and gene therapies, and monoclonal antibodies. Industry growth is driven by expanding therapeutic pipelines, a rise in biologics approvals, and the global trend toward targeted and personalized medicine. Production processes are being redesigned for increased efficiency, scalability, and cost-effectiveness due to the quick adoption of cutting-edge bioprocessing technologies, such as automation, continuous biomanufacturing, and single-use systems.

As chronic diseases like cancer, autoimmune diseases, and infectious diseases are becoming more common, there is a growing need for biologics. Consequently, biotechnology and pharmaceutical firms are expanding their ability to produce biologics. The global adoption of biologics is facilitated by technological advancements in quality control, analytical characterization, and upstream and downstream processing that improve yields, product safety, and regulatory compliance.

The global biologics manufacturing market is well-positioned to propel biopharmaceutical innovation in the future, enabling the safer, more efficient, and scalable production of life-saving therapies. This is due to the rise of novel therapeutic modalities, favorable regulatory frameworks, and sustained investment in biomanufacturing infrastructure.

 Request a free sample copy or view report summary: Biologics Manufacturing Market Report

Biologics Manufacturing Market Report Highlights

• By mode of manufacturing, contract manufacturing dominated the biologics manufacturing market with a market share in 2024. Biotechnology and pharmaceutical companies' increasing dependence on contract development and manufacturing organizations (CDMOs) to lower costs, manage risks, and gain access to specialized knowledge is causing this dominance. Due to CDMOs' capacity to offer scalable, GMP-compliant facilities and cutting-edge bioprocessing technologies, contract manufacturing has become the go-to model for large-scale and specialty biologics production.

• By modality, monoclonal antibodies (mAbs) led the biologics manufacturing market with a market share of 40.37% in 2024, because of their numerous therapeutic uses in infectious, autoimmune, and cancerous conditions. The demand for mAbs has been driven by their strong clinical success, good safety profile, and high specificity. Moreover, an expanding biosimilar pipeline and ongoing technological advancements in bioprocessing have reinforced their leadership as the most commercially successful biologic modality.

• By disease indication, oncology dominated the biologics manufacturing market with a market share of 38.46% in 2024. Strong investments in oncology-focused R&D, the growing global cancer burden, and the increasing use of targeted biologics such as immune checkpoint inhibitors and antibody-drug conjugates all contribute to this dominance. Oncology remains the top therapeutic area in biologics manufacturing thanks to a strong pipeline of cancer treatments and increasing regulatory approvals.

Biologics Manufacturing Market Segmentation

Grand View Research has segmented the biologics manufacturing market on the basis of mode of manufacturing, modality, disease indication, and region:

Biologics Manufacturing Mode Outlook (Revenue, USD Million, 2021 - 2033)

• Contract Manufacturing

• In-house manufacturing

Biologics Manufacturing Modality Outlook (Revenue, USD Million, 2021 - 2033)

• Monoclonal Antibodies (mAbs)

• Biosimilar & Recombinant Proteins

• Vaccines (recombinant/mRNA/Viral)

• Cell & Gene Therapies

• RNA-based Therapeutics

• Others

Biologics Manufacturing Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• Autoimmune Disorders

• Infectious Diseases

• Neurological Disorders

• Cardiovascular Disorders

• Other Disease Indications

Biologics Manufacturing Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Biologics Manufacturing Market

• Novartis AG

• Pfizer Inc

• Amgen Inc.

• Novo Nordisk A/S

• AbbVie Inc.

• Johnson & Johnson (Johnson & Johnson Services, Inc.)

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• F. Hoffmann La-Roche Ltd.

• Wuxi Biologics

• FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)

• Boehringer Ingelheim International GmbH

• Lonza

• Samsung Biologics